Espen Enerly started as a researcher at the Norwegian Cancer Registry in 2010. Espen has a PhD in biology from the University of Oslo in 2003, where he defended his thesis "Gene profiling using comparative and reverse genetics". He primarily works with harmonizing the Norwegian Cancer Registry's data to the OMOP data model and initiating research that uses OMOP. He also works with the INSPIRE project, which aims to improve drug use reporting in cancer treatment. Espen has overall responsibility for facilitating research collaboration between the Norwegian Cancer Registry and the pharmaceutical industry.
Espen Enerly genetically modified plants and fruit flies in the laboratory at the University of Oslo, which resulted in the degrees Cand. Scient, and Dr. Scient.
Here, the fascination for non-protein genes (RNA genes) was sparked, and an interest in its genomics was later developed and studied at the Institute of Bioinformatics (A*STAR, Singapore). Espen has later studied the RNA genes relation to breast cancer at the Radium Hospital in Norway.
He has been doing research in the field of pharmacoepidemiology, first related to HPV vaccination and later realted to cancer medicine.
Enerly defended his thesis at the Faculty of Biology at the University of Oslo in 2003 with the thesis «Gene profiling using comparative and reverse genetics»
Since 2010, Espen har worked as a researcher at the Cancer Registry of Norway, he works in the section of Molecular Epidemiology and infections.
He has primarily studied long-term follow up of subjects who received the HPV-vaccine.
Currently, he primarily works on harmonizing Cancer Registry data to the OMOP data model and initiating research that uses this data model.
He also work with the INcreaSe PharmaceutIcal Reporting (INSPiRE) project, which aims to improve the reporting of medicine used in cancer treatment.
Lately, he has also worked on how to better facilitate research collaboration between the Cancer Registry of Norway and the pharmaceutical industry as well as projects within pharmacoepidemiology. Read more about The Cancer Registry of Norway as facilitator for the healthcare industry.
Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES; CONNECT Public–Private Partnership Consortium; Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R; InPreD-Norway and National Molecular Tumor Board Consortium; IMPRESS-Norway Consortium; Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å. A national precision cancer medicine implementation initiative for Norway. Nat Med. 2022 May;28(5):885-887. doi: 10.1038/s41591-022-01777-4. PMID: 35513529.
Helland Å, Andersen KK, Myklebust TÅ, Johannesen TB, Aarøe J, Enerly E. EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study. Cancer Treat Res Commun. 2022;33:100636. doi: 10.1016/j.ctarc.2022.100636. Epub 2022 Sep 16. PMID: 36155129.
Enerly, E. , Holmstrøm, L. , Skog, A. , Knudsen, K.O. , Nygård, J.F. , Møller, B. and Ursin, G. 2021. INSPIRE: A new opportunity for cancer pharmacoepidemiology research. Norsk Epidemiologi. 29, 1-2 (Aug. 2021). DOI:https://doi.org/10.5324/nje.v29i1-2.4043.
Enerly E, Berger S, Kjær SK, Sundström K, Campbell S, Tryggvadóttir L, Munk C, Hortlund M; Thomas Group. Electronic address: thomas_group@merck.com; Joshi A, Saah AJ, Nygård M. Use of real-world data for HPV vaccine trial follow-up in the Nordic region. Contemp Clin Trials. 2020 May;92:105996. doi: 10.1016/j.cct.2020.105996. Epub 2020 Apr 1. PMID: 32247041.
Enerly E, Flingtorp R, Christiansen IK, Campbell S, Hansen M, Myklebust TÅ, et al. (2019) An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway. PLoS ONE 14(10): e0223612. https://doi.org/10.1371/journal.pone.0223612
Enerly E, Bonde J, Schee K, Pedersen H, Lönnberg S, Nygård M. Self-Sampling for Human Papillomavirus Testing among Non-Attenders Increases Attendance to the Norwegian Cervical Cancer Screening Programme. PLoS One. 2016 Apr 13;11(4):e0151978. doi: 10.1371/journal.pone.0151978. PMID: 27073929; PMCID: PMC4830596.
Rounge TB, Furu K, Skotheim RI, Haugen TB, Grotmol T, Enerly E. Profiling of the small RNA populations in human testicular germ cell tumors shows global loss of piRNAs. Mol Cancer. 2015 Aug 12;14:153. doi: 10.1186/s12943-015-0411-4. PMID: 26265322; PMCID: PMC4533958.
Nygård M, Saah A, Munk C, Tryggvadottir L, Enerly E, Hortlund M, Sigurdardottir LG, Vuocolo S, Kjaer SK, Dillner J. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine. Clin Vaccine Immunol. 2015 Aug;22(8):943-8. doi: 10.1128/CVI.00133-15. Epub 2015 Jun 17. PMID: 26084514; PMCID: PMC4519713.
Enerly E, Olofsson C, Nygård M. Monitoring human papillomavirus prevalence in urine samples: a review. Clin Epidemiol. 2013;5:67-79. doi: 10.2147/CLEP.S39799. Epub 2013 Mar 12. Erratum in: Clin Epidemiol. 2013 Sep 18;5:371. PMID: 23516174; PMCID: PMC3600937.
Enerly E, Bray F, Mellem C, Hansen BT, Kjølberg G, Dahl T, Johannesen TB, Nygård M. Quality assessment of the registration of vulvar and vaginal premalignant lesions at the Cancer Registry of Norway. Acta Oncol. 2012 Jan;51(1):45-50. doi: 10.3109/0284186X.2011.624545. Epub 2011 Nov 2. PMID: 22047060; PMCID: PMC3251004.
